Business
EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
- Interim six-month results show positive safety data, no dose limiting toxicities, no ocular serious adverse events (SAEs), and no drug-related systemic SAEs
About this update from Eyepoint, Inc.
[{"type":"text","content":"- Interim six-month results show positive safety data, no dose limiting toxicities, no ocular serious adverse events (SAEs), and no drug-related systemic SAEs\n - 76% and 53% of patients were rescue-free up to four and six months, respectively, following a single injection of EYP-1901\n - Stable best corrected visual acuity (BCVA), -2.5 letters, and central subfield thickness (CST), -2.7 μm, were achieved at the six-month visits\n - Overall treatment burden reduced by 79% at six months\n - Phase 2 clinical trials expected to initiate in 2022\n - Company to host conference call and webcast today at 12:00 p.m. EST, 11:00 a.m. CST\n\n\nWATERTOWN, Mass., Nov. 13, 2021 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced six-month interim data from the \"Durasert® and Vorolanib in Ophthalmology\" (DAVIO) Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting wet age-related macular degeneration (wet AMD). The data are being presented today at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting Retina Subspecialty Day in New Orleans by David S. Boyer, M.D., Senior Partner at Retina-Vitreous Associates Medical Group and adjunct clinical professor of Ophthalmology with the University of Southern California/Keck School of Medicine.\nExperience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8984051-eyepoint-pharmaceuticals-wet-amd-phase-1-davio-trial-efficacy-results/\n\"We are very encouraged by these data that reinforce EYP-1901's positive safety profile and its durable anti-VEGF activity up to six months so far in the majority of enrolled patients after a single intravitreal injection,\" said Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals. \"Wet AMD is a leading cause of blindness, and these data bring us one step closer to potentially changing the standard of care for patients by offering an in-office sustained delivery treatment option with the potential for up to every six-month dosing.\"The Phase 1 DAVIO clinical trial is an open-label, dose escalation clinical trial of EYP-1901 that enrolled 17 pa...